NI200700094A - Métodos para la neuroprotección - Google Patents

Métodos para la neuroprotección

Info

Publication number: NI200700094A
Authority: NI; Nicaragua
Prior art keywords: formula; group; phenyl; alkyl; methods
Prior art date: 2004-10-15

Application number

NI200700094A

Other languages

English (en)

Spanish (es)

Inventor

Roy E Twyman

Boyu Zhao

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-15

Filing date

2005-10-14

Publication date

2008-02-11

2005-10-14 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2008-02-11 Publication of NI200700094A publication Critical patent/NI200700094A/es

Links

230000004112 neuroprotection Effects 0.000 title abstract 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
229910052794 bromium Inorganic materials 0.000 abstract 1
229910052801 chlorine Inorganic materials 0.000 abstract 1
239000000460 chlorine Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
150000002367 halogens Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
229910052740 iodine Inorganic materials 0.000 abstract 1
239000011630 iodine Substances 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Endocrinology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Immunology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Rheumatology (AREA)

NI200700094A 2004-10-15 2005-10-14 Métodos para la neuroprotección NI200700094A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61940204P	2004-10-15	2004-10-15
US69840305P	2005-07-12	2005-07-12

Publications (1)

Publication Number	Publication Date
NI200700094A true NI200700094A (es)	2008-02-11

Family

ID=35840528

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NI200700094A NI200700094A (es)	2004-10-15	2005-10-14	Métodos para la neuroprotección

Country Status (14)

Country	Link
EP (1)	EP1802294A1 (pt)
JP (1)	JP2008516961A (pt)
KR (3)	KR20070085309A (pt)
AU (1)	AU2005295787A1 (pt)
BR (1)	BRPI0516112A (pt)
CA (1)	CA2584854A1 (pt)
EA (1)	EA200700871A1 (pt)
EC (1)	ECSP077395A (pt)
IL (1)	IL182432A0 (pt)
MX (1)	MX2007004491A (pt)
NI (1)	NI200700094A (pt)
NO (1)	NO20072444L (pt)
SG (1)	SG142306A1 (pt)
WO (1)	WO2006044472A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2509596B1 (en)	2009-12-08	2019-08-28	Case Western Reserve University	Gamma aminoacids for treating ocular disorders
US8609849B1 (en)	2010-11-30	2013-12-17	Fox Chase Chemical Diversity Center, Inc.	Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
KR20190081385A (ko)	2017-12-29	2019-07-09	강원대학교산학협력단	옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
FR3110393B1 (fr) *	2020-05-20	2022-05-06	Grn Consulting	Compose et composition pour induire une neuroprotection
KR20230044274A (ko) *	2020-08-31	2023-04-03	(주)바이오팜솔루션즈	신경퇴행성 질환의 예방 또는 치료용 페닐 알킬 카바메이트 화합물
KR20230051206A (ko)	2020-09-10	2023-04-17	(주)바이오팜솔루션즈	정신질환 치료 또는 완화용 설파메이트 유도체 화합물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5698588A (en) *	1996-01-16	1997-12-16	Yukong Limited	Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US20010034365A1 (en) *	1996-01-16	2001-10-25	Choi Yong Moon	Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
HUP0203198A3 (en) *	1999-08-20	2005-07-28	Ortho Mcneil Pharm Inc	Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
EP1383489B1 (en) *	2001-02-27	2007-05-09	Ortho-Mcneil Pharmaceutical, Inc.	Carbamate compounds for use in preventing or treating neurodegenerative disorders
DK1809273T3 (da) *	2004-09-16	2010-08-02	Janssen Pharmaceutica Nv	Anvendelse af 2-phenyl-1,2-ethandiol-(di)carbamater til behandling af epileptogenese

2005
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/pt not_active IP Right Cessation
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/es unknown
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 NI NI200700094A patent/NI200700094A/es unknown
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/ko not_active Ceased
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en not_active Ceased
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/ko not_active Ceased
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/ja active Pending
- 2005-10-14 EA EA200700871A patent/EA200700871A1/ru unknown
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/ko not_active Ceased
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/es unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
KR20090130175A (ko)	2009-12-18
IL182432A0 (en)	2007-09-20
KR20070085309A (ko)	2007-08-27
WO2006044472A1 (en)	2006-04-27
MX2007004491A (es)	2007-08-08
AU2005295787A1 (en)	2006-04-27
BRPI0516112A (pt)	2008-08-26
KR20110049901A (ko)	2011-05-12
CA2584854A1 (en)	2006-04-27
SG142306A1 (en)	2008-05-28
NO20072444L (no)	2007-06-14
ECSP077395A (es)	2007-05-30
EA200700871A1 (ru)	2007-10-26
JP2008516961A (ja)	2008-05-22
EP1802294A1 (en)	2007-07-04

Publication	Publication Date	Title
NI200800008A (es)	2010-11-25	Métodos para la neuroprotección
ECSP088172A (es)	2008-03-26	Metodos para tratar la epileptogenesis
CO6180427A2 (es)	2010-07-19	Tratamiento de los trastornos generalizados del desarrollo
NO20071921L (no)	2007-06-12	Fremgangsmater for behandling av epileptogenese og epilepsi
CO5601006A2 (es)	2006-01-31	Procedimiento para la preparacion de esteres de escopina
ECSP077395A (es)	2007-05-30	Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos
AR054524A1 (es)	2007-06-27	Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
CO6180505A2 (es)	2010-07-19	Metodos para el tratamiento de transtornos cocleares y vestibulares
AR052885A1 (es)	2007-04-11	Metodos para el control del intervalo qt
IL157590A0 (en)	2004-03-28	Carbamate compounds for use in preventing or treating bipolar disorder
AR033427A1 (es)	2003-12-17	Uso de compuestos carbamatos en el tratamiento del dolor
CO6160292A2 (es)	2010-05-20	Metodos de tratamiento de transtornos de comportamiento perturbador 877
EA200800422A1 (ru)	2008-10-30	Способы лечения заболеваний, обусловленных химическими веществами
AR077884A1 (es)	2011-09-28	(4-(5-aminometil- fenil)-piperidin-1-il)-1h-indol-3-il)-metanonas disustituidas
AR035757A1 (es)	2004-07-07	Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar
UY29158A1 (es)	2005-11-30	Metodos de tratamiento de la epileptogénesis y la epilepsia
PE20060559A1 (es)	2006-08-11	Compuestos derivados de carbamato para el tratamiento de trastornos relacionados con sustancias
CR9766A (es)	2008-09-09	Metodos para el tratamiento de trastornos relacionados con sustancias
MY136733A (en)	2008-11-28	Carbamate compounds for use in preventing or treating psychotic disorders
CY1110672T1 (el)	2015-06-10	Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης
AR032907A1 (es)	2003-12-03	Uso de compuestos carbamatos para la prevencion o tratamiento de trastornos de ansiedad